
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
The American Journal of Managed Care
over 28 years ago
Physicians' Perceptions of Managed Careover 28 years ago
The Pharmacoeconomic Benefits of Cholesterol Reductionover 28 years ago
The Neonatologist as Primary Care Physicianover 28 years ago
Menopause and Controversies in Hormone Replacement Therapyover 28 years ago
An Update on the Treatment of Premenstrual Syndromeover 28 years ago
Physicians' Perceptions of Managed Care





